Pacira BioSciences, Inc. (PCRX) stock intrinsic value fair value estimate & owner earnings analysis

Pacira BioSciences makes non-opioid pain medicines used around surgery. One product carries the company: EXPAREL, a long-acting liposomal form of the local anaesthetic bupivacaine that surgeons inject at the surgical site. It sold $575 million in 2025, 79% of the $726 million total. The rest comes from ZILRETTA, an extended-release steroid injection for knee osteoarthritis ($117 million, gained in the 2021 purchase of Flexion Therapeutics), and iovera, a cold-therapy nerve device ($24 million). In June 2026 Pacira agreed to sell iovera to Zimmer Biomet for $70 million upfront, plus up to $70 million more if iovera sales hit targets through 2031. Nearly all sales are to US hospitals and surgery centres. What the business earns. We measure the cash the owners could take out each year. We start with operating cash flow and remove three things: short-term swings in working capital, stock-based pay (a real cost, even though it isn't paid in cash), and the capital spending needed to keep the business running. On that basis Pacira earned about $133 million in 2023, $140 million in 2024 and $119 million in 2025. That works out to $2.56, $3.03 and $2.64 per diluted share. We count only the years since the Flexion deal (2022 onward), because earlier years describe a smaller, different company. Buybacks have cut the share count from about 46 million to about 40 million. Spending that cash also costs roughly $8 million a year in lost interest income. After both effects, we use about $117 million, or $2.90 per share, as today's level of earnings. The accounts carry large non-cash charges that we add back: about $57 million a year of amortisation on the ZILRETTA intangible assets, a $163 million goodwill write-down in 2024 and a $26 million write-down of an intangible asset in 2025. We don't treat those intangibles as permanent, though. The decline they represent shows up in each case as ZILRETTA losing patent protection in 2031. The write-downs of acquired businesses also tell us that Pacira's acquisitions have not all paid off. The key date. In April 2025 Pacira settled its patent case with Jiangsu Hengrui's eVenus unit and Fresenius Kabi. The settlement lets them sell a limited volume of generic EXPAREL in the US from early 2030. Their permitted share starts in the high single digits of US volume and rises to the low 30s by 2033 and the high 30s in 2036-2038. From 2039 they may sell without any limit. Two more Chinese-owned generic makers, WhiteOak and Qilu, filed their own challenges in October 2025. Pacira sued them in November 2025 on nine patents, which blocks FDA approval of their versions for up to 30 months. That case is unresolved. In 2024 a US court also ruled one EXPAREL patent invalid, so the patents are not beyond challenge. Medicare's separate payment for EXPAREL under the NOPAIN Act began in January 2025, and the law ends it on December 31, 2027 unless Congress extends it. Recent trend. Owner earnings fell about 15% in 2025. EXPAREL volume grew 6%, but deeper discounts to hospital purchasing groups cut the net price. Stock-based pay and development spending also rose. The first half of 2026 recovered: owner earnings rose about 14% on the first half of 2025 and EXPAREL sales rose 4%. We therefore assume the first year is flat, not continued decline and not the 14% gain. Base case ($14.71 per share). EXPAREL grows 2% in 2027, then 1% a year in 2028-2029 as the extra Medicare payment lapses. Costs rise about 3% a year, so earnings drift down to about $104 million by 2029. Generic entry then follows the settlement schedule, and we assume WhiteOak and Qilu end up with similar terms. EXPAREL's net price falls 3% a year from 2030. Management offsets about 60% of the lost profit with cost cuts. ZILRETTA holds at about $35 million of contribution until its patents expire in 2031, then declines 25% a year. When unlimited generics arrive in 2039, EXPAREL revenue falls about 70%, and earnings fade to nothing by 2044. We give no value to Pacira's development pipeline, including its gene therapy for knee arthritis. Pacira's own track record is buying products, not inventing new ones, so nothing in the filings supports counting on future launches. Nor do we count the iovera earn-out, which depends on Zimmer's sales. We do count the $70 million iovera upfront payment. Bull case ($28.31 per share). EXPAREL keeps growing 5% a year through 2029, the pace it reached in 2025 and early 2026, with costs rising 3%. Generics enter only at the settlement's limited volumes, EXPAREL's price slips just 1% a year, and management offsets 75% of lost profit. ZILRETTA declines only 15% a year after 2031. Some EXPAREL business survives 2039 before fading out by 2045. Bear case ($3.73 per share). The NOPAIN payment lapses and purchasing-group discounts keep growing, so EXPAREL sales are flat in 2027 and fall 3% in 2028. WhiteOak or Qilu then wins its patent case once the 30-month block ends, and unrestricted generics arrive in 2029. EXPAREL revenue falls to about a third of its 2028 level by 2031 and keeps shrinking. ZILRETTA volumes, already down 4% in 2025, keep falling. Costs are cut only slowly, and the company runs small cash losses from 2030 to 2034. In this case Pacira must also deal with its $287.5 million of 2.125% convertible notes due May 2029 as its earnings collapse. Cash of about $251 million at June 2026, plus the iovera proceeds, would cover most of that debt. Refinancing any remainder would cost more. The business still keeps a small positive value in this case, but only just. We discount all cash flows at 6%, close to the long-term US Treasury yield plus a small premium. We don't subtract debt, because interest is already paid out of the cash flow we measure. We cannot tell from the filings how much profit iovera contributes, so we treat its sale as neither adding nor removing earnings. What would make this wrong. On the upside: a court win or settlement that keeps WhiteOak and Qilu out until 2030 or later, an extension of the NOPAIN payment, or a new product. On the downside: an early loss in the WhiteOak/Qilu case, or bigger discounts on EXPAREL before 2030. The value turns almost entirely on one product and one patent timetable. Margin-of-safety price. With a dated patent cliff, one dominant product and a real risk of earlier generic entry, the margin-of-safety price is set about 45% below our base value, at $8.00 per share. From that price, the implied return depends on EXPAREL holding its protected position through 2029 as the base case assumes. The bear case shows that a loss is still possible.